(Q38177414)

30 August 2017

title

Challenges and recommendations for early identification of metastatic disease in prostate cancer (English)

1 reference

30 August 2017

1 reference

6

Susan F Slovin

1 reference

30 August 2017

E David Crawford

1

1 reference

30 August 2017

Nelson N Stone

2

1 reference

30 August 2017

Evan Y Yu

3

1 reference

30 August 2017

Phillip J Koo

4

1 reference

30 August 2017

Stephen J Freedland

5

1 reference

30 August 2017

Leonard G Gomella

7

1 reference

30 August 2017

E Roy Berger

8

1 reference

30 August 2017

Thomas E Keane

9

1 reference

30 August 2017

Paul Sieber

10

1 reference

30 August 2017

Neal D Shore

11

1 reference

30 August 2017

Daniel P Petrylak

12

1 reference

30 August 2017

Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group

13

1 reference

30 August 2017

language of work or name

English

0 references

publication date

8 January 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

83

1 reference

30 August 2017

issue

3

1 reference

30 August 2017

page(s)

664-669

1 reference

Characterising the castration-resistant prostate cancer population: a systematic review

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Pathogenesis of osteoblastic bone metastases from prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Mechanisms of cancer cell metastasis to the bone: a multistep process

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Differential expression of matrix metalloproteinase-2 expression in disseminated tumor cells and micrometastasis in bone marrow of patients with nonmetastatic and metastatic prostate cancer: theoretical considerations and clinical implications-an im

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Historical prostate cancer screening and treatment outcomes from a single institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Denosumab: a new option in the treatment of bone metastases from urological cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Intermittent androgen suppression for rising PSA level after radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Intermittent versus continuous androgen deprivation in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Abiraterone in metastatic prostate cancer without previous chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

ACR appropriateness criteria on metastatic bone disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Molecular imaging of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Imaging in prostate cancer staging: present role and future perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Pelvic lymph node dissection in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

[18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

Imaging metastatic bone disease from carcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.10.026

10.1016/J.UROLOGY.2013.10.026

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference